Helus Pharma (HLPS) to Report Phase 2 Data for HLP004 in Generalized Anxiety Disorder This Quarter

Helus Pharma (HLPS) will release Phase 2 trial results for its lead candidate HLP004 in generalized anxiety disorder in the first quarter of 2026. The data is expected to be released between March 15 and April 15, following a pre-specified protocol. The interim analysis aims to assess efficacy and safety, with a target of meeting primary endpoints in favor of HLP004. If positive, the results could support a New Drug Application in 2026.